Examples include combining epidermal growth factor (EGFR) inhibitors with standard cytotoxic chemotherapy for patients with KRAS and BRAF wild-type disease [5], treating patients with BRAF V600E-mutated cancer with dual BRAF and EGFR inhibition [6], combining KRAS G12C inhibitors with anti-EGFR therapies in KRAS G12C-mutated colorectal cancer [7], using HER2-directed therapies in HER2-amplified colorectal cancer [7], or treating NTRK fusion-positive colorectal cancers with NTRK inhibitors [8]. This evidence concerns the gene KRAS and colorectal cancer.